Jubilant Pharmova share news, announcements and annual reports
NSE: JUBLPHARMABSE: 530019Pharmaceuticals & BiotechnologySmall Cap
Jubilant Pharmova Limited · Formerly Jubilant Life Sciences · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Jun 1981 on BSE, Jun 2003 on NSE
Last close ₹923.80down ₹22.20 (2.35%)BSE ₹924.70
Share price at the NSE close on 30 Oct 2026. Previous close ₹946.00.
30 Oct: open ₹946.00, high ₹951.80, low ₹920.00
52-week range of traded prices to 30 Oct 2026
₹786.05Low, 9 Mar 2026₹1,183.00High, 4 Nov 2025
- Next results date: the board meets on 13 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹14,714 Cr422nd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 41.79
- P/E without one-offsPrice to earnings without one-off items. Market cap divided by core profit: the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, less one-off items (exceptional items and the result of businesses sold or closed). Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹59 crore of one-off items, the largest of them in the quarter to Dec 2025.
- 35.78
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 2.07
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.54%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 5.3%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹59 crore of one-off items, the largest of them in the quarter to Dec 2025.
- 6.2%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 7.3%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.45
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 56,22937.1% delivered
Jubilant Pharmova orders, deals and press releases
164 filed, newest first. Page 3 of 4.
Aug 2011
Jun 2011
May 2011
Mar 2011
Feb 2011
Dec 2010
Nov 2010
29 Nov · Business
Jubilant Life Sciences Limited had informed the Exchange that as per the Scheme, Jubilant Industries Ltd. at the meeting of their Board of Directors held on November 26, 2010, has allotted 79,64,056 equity shares of Rs. 10 each as fully paid up, to the shareholders of Jubilant Life Sciences Ltd. in the ratio of 1 (One) equity share of Rs. 10 each of Jubilant Industries Ltd., for every 20 (twenty) equity shares of Re. 1 each held in Jubilant Life Sciences Ltd.The Company has now informed the Exchange that as per the Scheme, Jubilant Industries Ltd. at the meeting of their Board of Directors held on November 27, 2010, has allotted 79,64,056 equity shares of Rs. 10 each as fully paid up, to the shareholders of Jubilant Life Sciences Ltd. in the ratio of 1 (One) equity share of Rs. 10 each of Jubilant Industries Limited, for every 20 (twenty) equity shares of Re. 1 each held in Jubilant Life Sciences Limited.29 Nov · Business
As per the Scheme, Jubilant Industries Ltd. at the meeting of their Board of Directors held on November 26, 2010, has allotted 79,64,056 equity shares of Rs. 10 each as fully paid up, to the shareholders of Jubilant Life Sciences Ltd. in the ratio of 1 (One) equity share of Rs. 10 each of Jubilant Industries Ltd., for every 20 (twenty) equity shares of Re. 1 each held in Jubilant Life Sciences Ltd.19 Nov · Business
Jubilant Life Sciences Limited had informed the Exchange that the Scheme of Amalgamation and Demerger among Jubilant Life Sciences Limited, Speciality Molecules Limited, Pace Marketing Specialities Limited and Jubilant Industries Limited has been filed with Registrar of Companies and has become effective from November 15, 2010. The Company further informed the Exchange that, as envisaged in the Scheme, the Company has on November 18, 2010 allotted 5,01,364 equity shares of Re.1 each to the shareholders of Pace Marketing Specialities Limited.8 Nov · Business
Hon'ble High Court of Judicature at Allahabad vide order dated October 28, 2010 received on November 02, 2010, has sanctioned the Scheme of Amalgamation & Demerger between Jubilant Life Sciences Limited (formerly Jubilant Organosys Limited); Specially Molecules Limited, Pace Marketing Specialities Limited & Jubilant Industries Limited. The company is awaiting Hon'ble High Court's Order in Form No.42 and will thereafter file certified copies of both Orders with Registrar of Companies. the Effective Date of the Scheme will be the date on which the said copies of the Orders are filed with the Registrar of Companies.
Sep 2010
28 Sep · Business
Following meetings were held on September 24, 2010 as per the Order of the Hon'ble High Court of Judicature at Allahabad: (1) Equity Shareholders of Jubilant Organosys Limited; (2) Secured Creditors of Jubilant Organosys Limited; (3) Unsecured Creditors of Jubilant Organosys Limited; (4) Unsecured Creditors of Speciality Molecules Limited; and (5) Equity Shareholders of Pace Marketing Specialities Limited. In the above meetings the Equity Shareholders/Creditors have approved the Scheme of Amalgamation and Demerger among Jubilant Organosys Limited, Speciality Molecules Limited, Pace Marketing Specialities Limited and Jubilant Industries Limited under sections 391/394 of the Companies Act, 1956.
Aug 2010
Jul 2010
May 2010
Apr 2010
1 Apr · Business
Vide its letter dated March 31, 2010 that "The Capital Issue Committee, a duly authorized committee of the Board of Directors of the Company (the 'Committee') had approved the price for issue of shares to Qualified Institutional Buyers, the Bid Closing Date and Placement Document in respect of such issue, the Committee at its meeting held today, has approved the allotment of 11,237,517 equity shares of Re. 1/- each at a price of Rs. 344.50 per share, aggregating to Rs. 387.13 crores to Qualified Institutional Buyers under Chapter VIII of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2009, as amended, against receipt of full payment of application monies in the escrow cash account opened by the Company". A copy of resolution passed at the meeting of the Capital Issue Committee of the Board of Directors held on March 31, 20010 shall be available on the NSE website (http://www.nseindia.com) under Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Mar 2010
30 Mar · Business
Jubilant Organosys Limited had informed the Exchange that the Capital Issue Committee, a duly authorized committee of the Board of Directors of the Company, (the "Committee") had approved the Preliminary Placement Document in respect of the issue of shares to Qualified Institutional Buyers, authorized the opening of the said issue and fixed the Bid Opening Date for the same. The Company has now informed the Exchange that the Committee at its meeting held on March 29, 2010, has decided to price the issue to Qualified Institutional Buyers at Rs. 344.50 per share i.e. at a premium of Rs. 343.50 per share. The number of shares will be 11,237,517 and the aggregate issue amount will be Rs. 387.13 crores. The Committee has fixed Bid Closing Date for the said issue as March 29, 2010.26 Mar · Business
Capital Issue Committee, a duly authorised committee of the Board of Directors of the Company (the "Committee"), at its meeting held on March 25, 2010, has approved the opening of an issue of equity shares of the Company of face value Re.1 /- each to Qualified Institutional Buyers under Chapter VIII of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2009. Further the copy of the Resolution passed at the meeting has been submitted to the Exchange. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Jan 2010
21 Jan · Business
Press release dated January 21, 2010, titled "Revenue up by 6% to Rs.961 crore; EBITDA up52% to Rs.238 crore; PAT up 215% at Rs. 101 crore". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Dec 2009
1 Dec · Business
Press release dated December 01, 2009, titled "Jubilant and Lilly Extend Drug Discovery Collaboration on Sucessful Delivery of Pre-clinical Candidates". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Nov 2009
24 Nov · Business
Press release dated November 23, 2009, titled "Jubilant Organosys, UAB and Southern Research Enter Into Drug Discovery Joint Venture". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.10 Nov · Business
Press release dated November 10, 2009, titled "Duke University & Jubilant Organosys Announce Intent to Enter Global Research and Drug Development Partnership". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Oct 2009
22 Oct · Business
Press release dated October 22, 2009, titled "Revenue for Q2 FY 2010 at Rs.933 crore, EBITDA for the quarter at Rs.192 crore with EBITDA margins of 20.5% and Net Profit at Rs.58 crore". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Jul 2009
14 Jul · Business
Press release dated July 14, 2009, titled "Q1 FY10 Revenues up 8% to Rs.896 crore; Q1 FY 10 PAT at Rs.126 crore ". Further the Company has also submitted a copy of Performance Highlights Q1 FY 2010. A copy of the press release and Performance Highlights shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Jun 2009
11 Jun · Business
Press release dated June 11, 2009, titled "Jubilant to Work with Endo Pharmaceuticals on Drug development,Collaboration to provide Endo Pharmaceuticals with new drug candidates in Oncology ". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
May 2009
5 May · Business
Press release dated May 05, 2009, titled "Jubilant Enters Research Collaboration with AstraZeneca". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.4 May · Business
Press release dated May 04, 2009, titled "DRAXIMAGE(R)'s generic Sestamibi Approved for launch in USA". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Apr 2009
28 Apr · Business
Press release dated April 28, 2009, titled "FY09 Revenues up 41% to Rs.3,518 crore; FY09 operating EBIDTA (excluding Forex impact) up 51% to Rs.716 crs". Further the Company has also submitted a copy of Performance Highlights Q4 and FY 2009. A copy of the press release and Performance Highlights shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.9 Apr · Business
Press release dated April 09, 2009, titled "Jubilant and Orion ink "Hybrid and Integrated" Drug Discovery Collaboration". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Mar 2009
12 Mar · Business
Press release dated March 11, 2009, titled "DRAXIMAGE, a Jubilant Organosys Company signs an agreement with Guerbet to distribute its nuclear medicine products in Europe". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.2 Mar · Business
Press release dated March 02, 2009, titled "Jubilant Receives Approvals for Sestamibi in Canada ". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Feb 2009
26 Feb · Business
"Further to our announcement dated February 10, 2009, February 19, 2009 and February 23, 2009, we wish to announce that, as advised by our Banker, all the Bonds accepted by the Company for repurchase, have been cancelled as per details below: (a) 3,000 Bonds due in 2010 of the aggregating principal amount of US$ 3.000 million; (b) 453 Bonds due in 2011 of the aggregating principal amount of US$ 45.300 million; The aggregate principal amount outstanding after cancellation of the repurchased Bonds is: (a) 49,657 Bonds due in 2010- outstanding principal amount of US$ 49.657 million; (b) 1,436 Bonds due in 2011- outstanding principal amount of US$ 143.600 million." A copy of the Press Release dated February 25, 2009 titled "Jubilant buys back FCCBs worth USD 59 million- Records cumulative gain of USD 25 million" shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Jan 2009
27 Jan · Business
Press release dated January 27, 2009, titled "Q3 FY09 Revenues up 42% to Rs. 910 crore; 9M FY09 Revenues up 49% to Rs. 2,677 crore; 9M FY09 EBITDA up 46% to Rs. 512 crore". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.21 Jan · Business
Press release dated January 21, 2009, titled "Jubilant Biosys Launches Legend NGSS(TM) Advanced Software Solution for High-Throughput Drug Molecule Screening". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.13 Jan · Business
Press release dated January 13, 2009, titled "Jubilant and BioLeap announce new partnership in Drug Discovery". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Nov 2008
17 Nov · Business
Press release dated November 17, 2008, titled "Jubilant augments Clinsys Clinical Research (R) through acquisition of TrialStat ClinicalAnalytics (R), an EDC platform". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Oct 2008
29 Oct · Business
Press release dated October 29, 2008, titled "Jubilant Strengthens its Business Model in North America - Strategically Aligns HollisterStier and Draxis-Announces New Leadership". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.14 Oct · Business
Press release dated October 14, 2008, titled "Q2 FY09 Revenues up 52% to Rs. 941 crore; Q2 FY09 EBITDA up 56% to Rs. 184 crore; H1 FY09 Revenues up 53% to Rs. 1,767 crore; H1 FY09 EBITDA up 64% to Rs. 355 crore; Expects to post more than 50% increase in Revenues for FY2009". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.3 Oct · Business
Press release dated October 03, 2008, titled "Jubilant Organosys and Lilly to Form Drug Development Joint Venture". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Jul 2008
15 Jul · Business
Press release dated July 15, 2008, titled "Q1 FY09 Revenues up 53% to Rs.826.6 crore; Pharma & Life Sciences Revenues increase 72%; Q1 FY09 EBITDA increases 62% to Rs.173.2 crore; Expects to post more than 50% Increase in Revenues for FY2009". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.14 Jul · Business
Press release dated July 14, 2008, titled "Jubilant in Drug Discovery partnership with Amgen Inc, USA". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
May 2008
29 May · Business
Press release dated May 28, 2008, titled "Jubilant successfully completes acquisition of Draxis for US$ 253 million". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.8 May · Business
Press release dated May 08, 2008, titled "Jubilant acquires Speciality Molecules Pvt Ltd., India; Acquisition to further strengthen company's Pyridine portfolio". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Apr 2008
22 Apr · Business
Press release dated April 22, 2008, titled "Q4 FY08 Revenues grown 49% to Rs.6,890 million; Net Profit at Rs.582 million; Pharma & Life Science revenues increase 102%; FY08 Revenues improved 38% to Rs. 24,889 million, PAT up 76% at Rs. 4,005 million; Pharma & Life Science revenues increase 71%; Board declares increased dividend at 150% for the year". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.7 Apr · Business
Press release dated April 04, 2008, titled "Jubilant To Acquire Draxis Health; All - Cash Transaction at US$6.00 Per Share". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.